BETA — Beta Drugs Cashflow Statement
0.000.00%
- IN₹17.46bn
- IN₹17.32bn
- IN₹3.62bn
- 83
- 15
- 55
- 51
Annual cashflow statement for Beta Drugs, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IAS | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 160 | 343 | 411 | 488 | 615 |
Depreciation | |||||
Non-Cash Items | 0.023 | -17 | -77.3 | -129 | -138 |
Other Non-Cash Items | |||||
Changes in Working Capital | -42.3 | -102 | -204 | -147 | -241 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 186 | 296 | 234 | 309 | 362 |
Capital Expenditures | -57.6 | -194 | -182 | -116 | -369 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -0.925 | -23.3 | -8.57 | -23.6 | 11.4 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -58.5 | -218 | -191 | -140 | -357 |
Financing Cash Flow Items | -24.2 | -28 | -24.1 | -28.2 | -69.9 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -77.1 | -9.73 | -24.7 | -74.9 | 1,179 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 50.4 | 69 | 18.4 | 94.7 | 1,184 |